Abstract:

IgA nephropathy (IgAN) is the most common primary glomerulonephritis in the world. 20%-40% of IgAN patients will eventually progress to chronic renal failure and end stage renal disease (ESRD). Sometimes complete remission cannot be achieved through rigorous blood pressure and proteinuria control or the use of renin-angiotensin system blockers, thus corticosteroids and immunosuppressive agents are needed. The effects of classic immunosuppressive agents such as azathioprine and cyclophosphamide have been proven by many studies, while their limitations lead to more studies on new immunosuppressive agents. This paper reviews applications and research progresses of new immunosuppressive agents for the treatment of IgAN.

Key words: IgA nephropathy, therapy, new immunosuppressive agent